SUMMIT, N.J. February 28, 2025 –True to this year’s American Academy of Allergy, Asthma & Immunology and the World Allergy Organization (AAAAI /WAO) Joint Congress’ theme, Climate Change and Allergic Diseases: Global Impact on Health, Kenvue will share new data on how a changing climate can impact allergy symptoms, as well as the latest advances in managing these. The meeting will be held February 28 to March 3 in San Diego, California.
“Allergy and asthma specialists are seeing the effects of changes in air quality and pollen seasons in patients, and we’re exploring how that may change our approach to allergy management. We’re looking forward to sharing these findings with over 5,000 leading researchers from around the world at AAAAI/WAO, and discussing how we meet these challenges to make a lasting impact on patient health with this expert global community,” said Michelle Bateson, Vice President of Global Self Care, Research and Development at Kenvue, “Advancing the wellbeing of people around the world is a key priority of our Healthy Lives Mission.”
Look for an abstract and poster of Kenvue’s study, “Increased Number of ALLERGYCAST® Users and Symptoms in the United States During 2023 Canadian Wildfire,” where researchers measured how allergy sufferers are affected by wildfires, which are likely made more frequent by a changing climate. Using the Zyrtec® ALLERGYCAST® app, they tracked reported nasal, ocular, and throat symptoms that were logged during a 2023 Canadian wildfire, which sent smoke across the Northeastern United States. New users of the ALLERGYCAST® app spiked and more symptoms were reported in the NE U.S. region during Canada’s wildfire phase, demonstrating a significant and widespread health consequence of climate change-driven natural disasters. The poster will be available all weekend in Hall A (Ground Level) of the San Diego Convention Center. The poster presentation will be held Saturday, March 2, 9:45 to 10:45 a.m. PST.
Kenvue’s interactive exhibit, “A Patient-Centric Approach to Allergy Management,” at Booth 1121 will engage healthcare professionals in quick, case-based scenarios. Providers can see virtual patients with different diagnostic profiles and lifestyles, choose from the latest allergy therapies, and see how those therapies perform in each scenario. Kenvue will also meet with Key Opinion Leaders in the allergy and immunology space to explore emerging trends, insights, and unmet needs in the field.
To learn more about the study, “Climate Change and Allergic Diseases: Global Impact on Health,” or to schedule interviews with author Domonique Crudup, PhD, Post-doctoral Scientist of Global Scientific Engagement at Kenvue, Maira Simoes, PhD, MBA, Manager of Global Scientific Engagement at Kenvue or Dr. Payel Gupta, MD, FACAAI, Medical Director of Allergy, Asthma & Immunology at Tono Health, please contact Kenvue R&D Media Relations.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of Zyrtec® ALLERGYCAST®. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of [Kenvue][Kenvue Inc. (“Kenvue”)] and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
R&D Media Relations
Meghan Harding
MHardin1@kenvue.com